Contact Us

publications

TEXT SIZE

meeting highlights    back A Comprehensive Guide to Kos 2007 Review of the XIth International Myeloma Workshop Summaries from the workshop sessions in Kos, Greece - 5–30 June, 2007

	02.11.08
Be the first to comment Name Email Address URL Remember personal info? Comments (You may use HTML tags for style)	print share |  related articles

KOS 2007: Molecular Principles Underlying Myeloma
	P. Leif Bergsagel, MD Mayo Clinic Scottsdale, AZ, USA

---

KOS 2007: Molecular Lesions in Multiple Myeloma
	Michael Kuehl, MD National Cancer Institute Bethesda, MD, USA

---

KOS 2007: Towards a Molecular-Based Risk Stratification of Multiple Myeloma
	J.D. Shaughnessy Jr., MD Donna D. and Donald M. Lambert Laboratory for Myeloma Genetics Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences Little Rock, Arkansas, USA

---

KOS 2007: Clinical and Pathological Implications of Myeloma Subtypes
	Rafael Fonseca, MD Mayo Clinic Scottsdale, AZ, USA

---

KOS 2007: Prognostic implications of FISH karyotyping in Myeloma
	Herve Avet-Loiseau, MD Laboratory of Hematology University Hospital Nantes, France

---

KOS 2007: Single Nucleotide Polymorphism Models in Myeloma - From the Bank On A Cure SNP Chip
	Brian Van Ness, PhD Bank On A Cure® International Myeloma Foundation

---

KOS 2007: Animal Models of Multiple Myeloma: An Overview
	Karin Vanderkerken, MD Vrije Universiteit Brussel (VUB) Department Hematology and Immunology Brussels, Belgium

---

KOS 2007: The Scid-hu model for Multiple Myeloma
	Joshua Epstein, MD Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences Little Rock, Arkansas, USA

---

KOS 2007: Chromosomal and epigenetic abnormalities in MGUS and MM Post-MGUS
	Johannes Drach, MD Medical University of Vienna Department of Medicine I Clinical Division of Oncology Vienna, Austria

---

KOS 2007: Microarray Analysis to Predict Response to Thalidomide and the IMIDs
	Shaji Kumar, MD Mayo Clinic Hepatology Department Rochester, MN, USA

---

KOS 2007: Mosaicism of Vessels in Patients with Myeloma and Therapeutic Approaches
	Angelo Vacca, MD Department of Internal Medicine and Clinical Oncology University of Bari Medical School Bari, Italy

---

KOS 2007: The Role of T-Cells in Multiple Myeloma
	Douglas Joshua, MD University of Sydney Royal Prince Alfred and Concord Hospital Camperdown, Australia

---

KOS 2007: Genetic Model of Multiple Myeloma
	Ruben Carrasco, MD Dana Farber Cancer Institute Medical Oncology Dept. Boston, MA, USA (Presentation given by Giovanni Tonon)

---

KOS 2007: From Oncogenome Mining to Functional Validation of Multiple Myeloma Cancer Genes
	Giovanni Tonon, MD Dana Farber Cancer Institute Medical Oncology Dept. Boston, MA, USA

---

KOS 2007: Induction of Multi-Lineage Markers and Their Down-Regulation by IL-6 in Human Myeloma Cells
	Michio Kawano, MD Laboratory of Cellular Signal Analysis Graduate School of Medicine Yamaguchi University Ube, Japan

---

KOS 2007: Pathophysiology of Myeloma Bone Disease
	Peter Croucher, MD Section of Musculoskeletal Science University of Sheffield Medical School Sheffield, UK

---

KOS 2007: The Role of Bisphosphonates in the Management of Myeloma
	James Berenson, MD Institute for Myeloma and Bone Cancer Research Los Angeles, CA, USA

---

KOS 2007: The Role of Biochemical Markers of Bone Metabolism in Multiple Myeloma. Adverse Events of Bisphosphonates Administration
	Evangelos Terpos, MD Department of Hematology & Medical Research 251 General Airforce Hospital Athens, Greece

---

KOS 2007: New Agents Targeting Myeloma Bone Disease
	G. David Roodman University of Pittsburgh Medicine/Hematology-Oncology Pittsburgh, PA, USA

---

KOS 2007: A transgenic mouse model that faithfully reproduces the pathogenesis, biology and clinical features of multiple myeloma
	Marta Chesi, MD Comprehensive Cancer Center Mayo Clinic Arizona Scottsdale, AZ, USA

---

KOS 2007: The Treatment of Relapsed and Refractory Myeloma: Focus on Bortezomib and Bortezomib-based Combinations
	Paul Richardson, MD Medical Oncology Dana Farber Cancer Institute Harvard Medical School Boston, MA, USA

---

KOS 2007: Lenalidomide for the Treatment of Relapsed or Refractory Myeloma
	Donna Weber, MD The University of Texas MD Anderson Cancer Center Houston, TX, USA

---

KOS 2007: Impact of novel agents in patients with poor prognosis myeloma defined by unfavorable cytogenetics, high age, and renal failure
	Heinz Ludwig, MD Department of Medicine I Center of Oncology and Hematology Wilhelminenspital Vienna, Austria

---

KOS 2007: International Staging System for Multiple Myeloma
	Philip Greipp, MD Mayo Clinic Internal Medicine Rochester, Minnesota

---

KOS 2007: The Role of Thalidomide in Myeloma Patients Eligible for High-Dose Therapy
	Michele Cavo, MD Seràgnoli Institute of Hematology and Medical Oncology Bologna UniversitySchool of Medicine Italy

---

KOS 2007: Role of Bortezomib in Myeloma Patients Eligible for High-Dose Therapy
	Sundar Jagannath, MD St. Vincent's Comprehensive Cancer Center New York, NY, USA

---

KOS 2007: The Role of Lenalidomide in Myeloma Patients Eligible for High Dose Therapy
	Vincent Rajkumar, MD Division of Hematology Mayo Clinic Rochester, Minnesota, USA

---

KOS 2007: Frontline Treatment in Patients Not Eligible for Stem Cell Transplant
	Thierry Facon, MD CHU Lille, France

---

KOS 2007: Management of Toxicities from Novel Agents
	Mohamad Hussein, MD Multiple Myeloma Clinical Research Clinical Director H. Lee Moffitt Cancer & Research Institute Tampa, Florida, USA

---

KOS 2007: Prognostic Factors for Multiple Myeloma in the Era of Novel Therapies
	Joan Bladé Hematology Department Institut of Hematology and Oncology IDIBAPS, HospitalClínic Barcelona, Spain

---

KOS 2007: Debate I - Should CR Achievement Be a Major Treatment Objective? Introduction
	Raymond Alexanian, MD

---

KOS 2007: Debate I - Should CR Achievement Be a Major Treatment Objective? Yes!
	Jean Luc Harousseau, MD Hôpital Hôtel Dieu Nantes, France

---

KOS 2007: Debate I - Should CR Achievement Be a Major Treatment Objective? No!
	Mario Boccadoro, MD Divisione di Ematologia dell’Università di Torino Azienda Ospedaliera San Giovanni Battista Torino, Italy Includes questions and comments from the audience.

---

KOS 2007: Establishment of an Amyloid-Forming Human Cell Line
	Bonnie Arendt, MD Dept. of Immunology Mayo Cinic Rochester, MN, USA

---

KOS 2007: Targeting Beta 1 Integrin Mediated Survival Signals in Multiple Myeloma
	Lori Hazlehurst, PhD Moffitt Cancer Center Tampa, Florida, USA

---

KOS 2007: Response by SFLC and Marrow Flow Cytometry in MRC Myeloma IX
	Roger Owen, MD HMDS Laboratory and Department of Haematology Leeds Teaching Hospitals Leeds, UK

---

KOS 2007: Final Results of a Phase II PETHEMA Trial of Alternating Bortezomib and Dexamethasone as Induction Regimen Prior Autologous Stem Cell Transplantation (ASCT) in YOunger Patients with Multiple Myeloma (MM): Efficacy and Clinical Implications of Tumor Response Kinetics
	Laura Rosiñol, MD Hospital Clinic Barcelona, Spain

---

KOS 2007: Long-Term and Updated Results of the IFM99-03 and IFM99-04 ProtocolsComparing Autologous Followed by RIC-Allogeneic Transplantation and Double Transplant in High-Risk De Novo Multiple Myeloma
	Philippe Moreau, MD on Behalf of the IFM Group France

---

KOS 2007: Double versus Single Autologous Stem-Cell Transplantation for Multiple Myeloma: a Region Based Study in 485 patients from the Nordic Area
	H.E. Johnsen, MD Department of Hematology Huddinge University Hospital Sweden

---

KOS 2007: Prognostic impact of postransplantation complete remission (CR) in multiple myeloma(MM). Final results of a prospective study in a series of homogenously treated patients
	Joaquin Martinez-Lopez the Grupo Espanol de Mieloma (GEM) Spain

---

KOS 2007: Drug Resistance in Myeloma
	W.S. Dalton, MD H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, USA

---

KOS 2007: AKT as a Therapeutic Target in Multiple Myeloma
	Noopur Raje, MD Massachusetts General Hospital Cancer Center Boston, MA, USA

---

KOS 2007: DNA Vaccines to Suppress Myeloma
	Freda Stevenson, MD Molecular Immunology Group Cancer Sciences Division Tenovus Laboratory Southampton University Hospitals Trust Southampton, UK

---

KOS 2007: Novel Immunotherapy Strategies in Multiple Myeloma
	Nikhil Munshi, MD Dana Farber Cancer Institute Boston MA, USA

---

KOS 2007: Single VS Double Autologous Transplant
	Hartmut Goldschmidt, MD Medizinischen Universitätsklinik und Poliklinik V University of Heidelberg Heidelberg, Germany

---

KOS 2007: Autologous Stem Cell Transplantation for MM: Analysis of Prognostic Factors
	Hermann Einsele, MD Medizinische Klinik und Poliklinik I Bayerische Julius-Maximilians-Universität Würzburg

---

Kos 2007: Allogeneic Transplantation in Multiple Myeloma
	Henk Lokhorst, MD Dept. of Hematology University Medical Center Utrecht, the Netherlands

---

KOS 2007: Donor lymphocyte infusion and other posttransplant Strategies After Allografting in Multiple Myeloma
	Nikolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg-Eppendorf, Germany

---

KOS 2007: Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM)
	Robert A. Kyle, MD Mayo Clinic Rochester, MN, USA

---

KOS 2007: Solitary Bone and Extramedullary Plasmacytoma
	Raymond Alexanian, MD M. D. Anderson Cancer Center University of Texas Houston, TX, USA

---

KOS 2007: AL Amyloidosis: Diagnosis and Prognosis
	Giampaolo Merlini, MD Amyloidosis Center Fondazione IRCCS Policlinico San Matteo University of Pavia Pavia, Italy

---

KOS 2007: AL Amyloidosis: Response, Assessment, and Treatment
	Morie A. Gertz, MD Mayo Clinic Rochester, MN, U.S.A.

---

KOS 2007: The Role of High-Dose Therapy in AL-Amyloidosis
	Raymond Comenzo, MD Hematology Service Department of Medicine Memorial Sloan-Kettering Cancer Center New York, NY, USA

---

KOS 2007: Light Chain Deposition Disease
	Nelson Leung, MD Mayo Clinic Rochester, MN, USA

---

KOS 2007: What’s New About the POEMS Syndrome?
	Angela Dispenzieri, MD Mayo Clinic Cancer Center Rochester, MN, USA

---

KOS 2007: Paraproteinemia Related Neuropathies
	Eduardo Nobile-Orazio, MD Department of Neurological Sciences Milan University Milan, Italy

---

KOS 2007: High-Resolution Mapping of Common Gains and Losses in Myeloma
	Jonathan Keats,MD Mayo Clinic Comprehensive Cancer Center Scottsdale, Arizona, USA

---

KOS 2007: Microchips for Optimized Fish Screening in Myeloma
	Vincent Sieben Department of Electrical & Computer Engineering University of Alberta Edmonton, Canada

---

KOS 2007: Gene Expression Profiles as Prognostic Factors for High-Dose Therapy and Bortezomib in Patients with Multiple Myeloma
	Annemiek Broyl, MD Department of Hematology Erasmus Medical Center Rotterdam, The Netherlands

---

KOS 2007: Cathepsin G is Upregulated in Patients Treated with IMIDS
	Suzanne Lentzsch, MD University of Pittsburgh Cancer Institute Pittsburgh, PA, USA

---

KOS 2007:Melphalan-Prednisone-Thalidomide (MP-T) is Also Superior to Melphalan-Prednisone (MP) in Patients 75 Years of Age or Older with Untreated Multiple Myeloma (MM). Preliminary Results of the Randomized, Double-Blind, Placebo Controlled IFM 01-01 Trial
	Cyrille Hulin, MD Itergroupe Francophone du Myélome

---

KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM? Introduction
	Jean Luc Harousseau, MD

---

KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM? NO
	Jean-Paul Fermand, MD Department of Immuno-Hematology Hopital Saint-Louis, France

---

KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in mm? YES
	Bart Barlogie, MD Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences Little Rock, AR, USA

---

KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM? Q & A
	Questions from Dr. Harousseau and the audience.

---

KOS 2007: The Importance of New and Evolving Response Criteria
	Brian G.M. Durie, MD Samuel Oschin Comprehensive Cancer Institute Cedars Sinai Medical Center Los Angeles, CA, USA

---

KOS 2007: Individualizing Treatment in the Area of Multiple Novel Agents
	Jesús San Miguel, MD Hospital Clinico Universitario Universidad de Salamanca Salamanca, Spain

---

KOS 2007: European Myeloma Network: The Present and the Future
	Pieter Sonneveld The European Myeloma Network (EMN)

---

KOS 2007: Future Perspectives in the Management of Myeloma
	Kenneth C. Anderson, MD Dana-Farber Cancer Institute Boston, MA, USA

---